Multinational medical companies use theExpo platform to quickly 'integrate' into China
At the 5th China Import Expo in Shanghai,two achievements of Boston Scientific's "localization strategy" werepresented for the first time, including the Polaris Intravascular UltrasoundSystem "The other is Boston Scientific's first medical device developedand produced in China, the "Fusion Wing" single-use radiofrequencyablation electrode.
The Fair actively advocates"exhibits into commodities, exhibitors into investors". "We takeadvantage of the international cooperation platform effect of the Fair tocontinuously expand the local circle of friends, embed the domestic medical andhealth care ecological chain, and promote the global innovation achievements tothe Chinese market." David Zhang, President of Boston Scientific GreaterChina, told CNN: "The four years that the Fair is getting better andbetter are also the four years that Boston Scientific's localization isaccelerating."
Benefiting from the "Expoeffect", many of Boston Scientific's innovative products showcased at theExpo have been turned from exhibits to commodities, such as the Rimon ThermalSteam Therapy Device and the single-use prostate thermal steam therapy deviceRimon System, both approved and put into clinical use in China this year, withits market launch process a year and a half to two years earlier than theconventional model. The launch process is one and a half to two years earlierthan the conventional model. In addition, three other exhibits from theprevious Expo have embarked on the "highway" of access and areexpected to enter the Chinese market ahead of schedule.
This year, Boston Scientific registeredthe establishment of Boston Scientific Medical Technology (Shanghai) Co. JunZhang said, "We will continue to cultivate the local direction firmly, inthe research and development, introduction, production, professional educationand other dimensions, a comprehensive increase in localization, and the localmedical ecosystem symbiosis, to better meet the unmet needs of Chinese doctorsand patients, to help achieve the strategic goals of Health China 2030."
Thermo Fisher Scientific broughtdiversified solutions for the research, prevention, diagnosis and treatment ofvarious diseases at the Expo. It is worth mentioning that the company has setup a special exhibition area at the Expo, detailing its continuous localizationin China over the years and working with local partners to promote innovationand sustainable social development.
2026-09-30
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Eastern Shenghong Projects First-Half Profit of 5 Billion Yuan – A Collective Turnaround for the Four Major Private Refiners? Is the Chemical Sector Rebounding?
-
Melamine Prices Rise Locally, Short-term Signals Strengthen but Long-term Trend Remains Weak
-
Business Society’s PTA Market Outlook on August 26, 2026: Volatile
-
Insufficient downstream demand for DMF leads to a generally narrow and weak market performance
-
Business Society’s Market Outlook for Ammonium Sulfate on September 1, 2026: Volatile with a Slight Bullish Bias
-
Business Society’s Market Outlook for Petroleum Coke on August 27, 2026: Volatile